This study investigates advanced solid tumors with KRAS mutations. The purpose of this study is to evaluate the safety and tolerability of an investigational medication in adults with these conditions.
The study focuses on assessing the safety, tolerability, and preliminary clinical activity of the investigational medication. It also looks at how the body absorbs and processes the medication.
- Who can participate: Adults with advanced solid tumors with KRAS mutations who have not had prior treatment with a KRAS inhibitor may be eligible. Participants should have an ECOG performance status of 0 or 1 and adequate organ function.
- Study details: Participants will take the investigational medication to evaluate its effects. The study will include a dose escalation and dose expansion phase to assess different doses.
How understandable was the trial content above?
Hard to understand
Easy to understand